ClinicalTrials.gg
RecruitingNCT06833749Updated Feb 19, 2025

Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis

A Phase 2 interventional study of KBP-336 and Placebo in Osteoarthritis in the Knee and Obesity, sponsored by KeyBioscience AG. Recruiting at 20 sites in 6 countries. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2025-02-19.

Sponsored by KeyBioscience AG · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 97 studies in Obesity with a site in Czechia — 26 open to participants now, 46 under way, 32 of them phase 3. Obesity · Czechia.

Planned enrollment
37th of 88
600 · median 478
Started
2025
with 20 others
Phase 2
7 of 97
1 open now
Primary completion
2026-11
later than 5 of 45 live
Registered
61st of 97
by date

Among the 97 studies in Obesity with a site in Czechia, this one is the 37th largest by planned enrollment of the 88 interventional ones that give a count, is one of 21 that started in 2025, is one of 7 in phase 2, reaches primary completion later than 5 of the 45 other live ones, and was the 61st registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

26 of the 97 studies in Obesity with a site in Czechia are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies in Obesity with a site in Czechia, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if KBP-336 works to treat pain in osteoarthritis in individuals living with obesity. It will also learn about the effects on other parameters, such as quality of life and metabolism, as well as safety of KBP-336. The main questions it aims to answer are:

  • Does KBP-336 lower knee pain from osteoarthritis in individuals with obesity
  • Does KBP-336 lower bodyweight in the same population. Researchers will compare KBP-336 to a placebo (a look-alike substance that contains no drug) to see if KBP-336 works to pain and obesity

Participants will:

  • Take KBP-336 or a placebo every week for 6 months
  • Visit the clinic once every 2 weeks for checkups and tests
  • Keep a diary of their symptoms and the amount of medication they use in addition to KBP-336
03

Conditions studied

  • Osteoarthritis in the Knee
  • Obesity

Keywords

  • Obesity
  • Osteoarthritis
  • KBP-336
  • Pain
  • Phase 2
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant is able to read and understand the language and content of the study material and provide written .
  2. Willing and able to comply with study requirements and instructions
  3. A diagnosis of OA of the target knee based on American College of Rheumatology (ACR) clinical and radiographic criteria(31), with OA symptoms (as reported by the participant) that have been present for at least 3 months prior to screening
  4. Radiological OA grade 2 or 3 of the target knee, using the Kellgren-Lawrence method as graded by a central reader on a Fixed-Flexion X-ray obtained during screening, or on a recent (within 6 months) X-ray which fulfills the protocol specifications for reading
  5. Age ≥ 45 years of either sex
  6. (BMI) ≥ 30 kg/m2
  7. Good health, defined as no significantly relevant medical history or findings on physical examination, vital signs, , and laboratory results in the opinion of the investigator.
  8. Intolerance or insufficient pain relief with standard of care (e.g. physiotherapy, paracetamol, local or systemic NSAID, short term opioid use, injections of hyaluronic acid, or ) for symptomatic OA in the index knee in the opinion of the investigator.
  9. WOMAC pain subscale score in target knee at screening AND baseline ≥20 (0-50 scale)
  10. Willing to withdraw from any pain medication including, but not limited to, Opioids (including semisynthetic opioids), Non-Steroidal Anti-inflammatories (NSAIDs, with the exception of low-dose aspirin for thromboprophylaxis), COX-2 inhibitors, Topical medication, and Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs e.g. Duloxetine) and only use the allowed Rescue Medications from baseline to Visit 13/ET (maximum 4000 mg paracetamol per day)

Exclusion criteria

Exclusion Criteria:

  1. Partial or complete joint replacement of either knee
  2. Target knee surgery or arthroscopy within 1 year prior to screening
  3. Diagnosis of OA resulting from trauma within the last 5 years
  4. Pain of the contralateral knee exceeding that of the target knee at the baseline visit, as measured by the WOMAC pain subscale
  5. Planned major surgery within the next 6 months
  6. Uncontrolled thyroid disease in the opinion of the Investigator based on medical history and laboratory results collected in screening
  7. Participant-reported weight loss >5% of body weight within the last 6 months of the screening visit
  8. Bariatric surgery within the last 12 months of the screening visit
  9. Current comorbid condition, other than OA, affecting target knee or systemic illness known to be significantly associated with arthritis or joint pathology affecting any joint, including but not necessarily limited to endocrinopathies, inflammatory, or disease with significant joint involvement (e.g., Rheumatoid Arthritis); Seronegative Spondyloarthropathies (e.g. Ankylosing Spondylitis, Psoriasis arthritis, Reactive arthritis)
  10. Conditions significantly affecting joint and bone health, in the opinion of the Investigator should be excluded (including but not limited to atrophic or hypotrophic OA, subchondral insufficiency fracture, osteonecrosis, osteoporotic fractures, excessive malalignment of the knee or severe chondrocalcinosis)
  11. Active comorbid condition other than OA (e.g radicular back pain, bursitis, tendinitis) significantly affecting target knee pain reporting in the opinion of the investigator.
  12. A Patient Health Questionnaire-9 (PHQ-9) score of ≥ 15 at screening
  13. History of gout, or pseudogout, with high likelihood of flare up during trial participation that would require NSAID treatment, in the opinion of the investigator
  14. Hip dislocation and congenital hip dysplasia with degenerative joint disease should be excluded.
  15. Participation in any previous DACRA/amylin study
  16. History or presence of neurological disease or psychiatric disorder in the opinion of the investigator
  17. Intra-articular injection of within 3 months or hyaluronic acid within 6 months of screening in the target knee or into any other major joint within 30 days prior to screening (for extended-release corticosteroid injections: within 6 months in target knee and 3 months into any other major joint).
  18. Systemic corticosteroid treatment for the treatment of musculoskeletal conditions of more than 14 days during the past 6 months prior to screening.
  19. Any pharmacological or non-pharmacological treatment primarily targeting OA started or changed during the 4 weeks prior to randomization or likely to be changed during the duration of the study
  20. Treatment with medication for obesity, including GLP-1 analogues, unless the dose of use has been stable for at least six months prior to screening
  21. Vitamin D deficiency defined as blood 25-OH D3 concentration ≤25 nmol/L. Vitamin D supplementation and subsequent rescreening is allowed
  22. Presence or history of clinically significant allergies, including relevant drug or allergy
  23. Current or treatment for malignancy within the past five years, apart from resected basal cell carcinoma, squamous skin cell carcinoma, or resected cervical atypia or carcinoma in situ, unless affecting the target knee area.
  24. History of alcohol or drug abuse within 5 years prior to screening, in the opinion of the Investigator.
  25. Use of an drug within 90 days prior to screening
  26. For women of :

    1. Pregnancy (i.e. positive serum pregnancy test at screening) or breastfeeding
    2. Failure to agree to practice a highly effective method of (see Appendix 2), from enrolment up to at least 3 months after the study end
  27. For sexually active men with a female partner of childbearing potential:

    1. Failure to agree to ensure that their female partners use a highly effective method of contraception (see Appendix 2) from enrolment up to at least 3 months after the study end
    2. Failure to agree not to donate sperm throughout the study and at least 3 months after the study end
  28. Unsuitable for study participation for any reason in the opinion of the Investigator.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
600 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Active comparator
    KBP-336 Dose 1

    Drug: KBP-336

  • Active comparator
    KBP-336 Dose 2

    Drug: KBP-336

  • Active comparator
    KBP-336 Dose 3

    Drug: KBP-336

Interventions

  • DrugKBP-336

    KBP-336 is a long acting Dual Amylin and Calcitonin Receptor agonist designed for weekly administration through subcutaneous injection.

  • DrugPlacebo

    Placebo to match KBP-336

06

What researchers measure

Primary outcomes

  1. The proportional change in body weight from baseline to endpoint

    Time frame: 183 Days

  2. The change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scale from baseline to endpoint

    Higher scores indicate worse pain, stiffness, and functional limitations. The WOMAC measures five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68). Following assessment the scores are normalized.

    Time frame: 183 Days

Secondary outcomes

  1. Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) stiffness and function scales during the trial and at Day 183

    Higher scores indicate worse pain, stiffness, and functional limitations. The WOMAC measures five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68). Following assessment the scores are normalized.

    Time frame: 183 Days

  2. Proportion of subjects reaching ≥5, ≥10 or ≥15% weight loss from baseline at Day 183

    Time frame: 183 Days

  3. Proportion of subjects reaching ≥30 and ≥50% reduction in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scale from baseline at Day 183

    Higher scores indicate worse pain, stiffness, and functional limitations. The WOMAC measures five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68). Following assessment the scores are normalized.

    Time frame: 183 Days

  4. Change from baseline in Assessment of Quality of Life 8 Dimensions (AQol 8D) at Day 183

    The AQoL-8D consists of eight dimensions measured by 35 items with four to six levels each. Five out of eight dimensions assess the psychosocial domains of health: happiness, coping, self-worth, relationships, and mental health. The scale if from 0 - 1 and is calculated using (https://www.aqol.com.au/index.php/scoring-algorithms)

    Time frame: 183 Days

  5. Change from baseline in Assessment of Quality of Life 8 Dimensions (AQol 8D) subscore Independent living at Day 183

    The AQoL-8D consists of eight dimensions measured by 35 items with four to six levels each. Five out of eight dimensions assess the psychosocial domains of health: happiness, coping, self-worth, relationships, and mental health. The scale if from 0 - 1 and is calculated using (https://www.aqol.com.au/index.php/scoring-algorithms)

    Time frame: 183 Days

  6. Change from baseline in the weekly average of daily pain using the Numerical Rating Scale (NRS) during the trial, and at Day 183

    The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable").

    Time frame: 183 Days

  7. Area under the curve from baseline in the weekly average of daily pain using the Numerical Rating Scale (NRS) to Day 183

    The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable").

    Time frame: 183 Days

  8. Change from baseline to Day 183 in waist-to-hip ratio

    Time frame: 183 Days

  9. Change from baseline in whole body composition by DXA at Day 183

    Time frame: 183 Days

  10. Change from baseline in bone mineral density of the lumber spine, femoral head, and total hip by DXA at Day 183

    Time frame: 183 Days

  11. Change from baseline in Patient Global Assessment at Day 183

    Time frame: 183 Days

  12. Outcome Measures in Rheumatology (OMERACT) - Osteoarthritis Research Society International (OARSI) responder rates at Day 183

    Time frame: 183 Days

  13. Average weekly days using rescue medication

    Time frame: 183 Days

07

Study locations

3 of 20 sites recruiting
  • Pratia Brno, s.r.o
    Brno, Czech Republic
    Not yet recruiting
  • L.K.N. Artrocentrum
    Hlučín, Czech Republic
    Not yet recruiting
  • Medical Plus, s.r.o
    Hradiště, Czech Republic
    Not yet recruiting
  • Pratia Pardubice a.s.
    Pardubice, Czech Republic
    Not yet recruiting
  • Affidea Praha s.r.o
    Prague, Czech Republic
    Not yet recruiting
  • Pratia Prague, s.r.o
    Prague, Czech Republic
    Not yet recruiting
  • Sanos Clinic Nordjylland
    Gandrup, Denmark
    Recruiting
  • Sanos Clinic Herlev
    Herlev, Denmark
    Recruiting
  • Sanos Clinic Syddanmark
    Vejle, Denmark
    Recruiting
  • Hong Kong Center for Clinical Research
    Hong Kong, Hong Kong
    Not yet recruiting
  • Timofei Mosneaga Republican Clinical Hospital
    Chisinau, Moldova, Republic of
    Not yet recruiting
  • IMSP Sptalul Clinic Municipal "Sfanta Treime"
    Chișinău, Moldova, Republic of
    Not yet recruiting
  • PMSI Cardiology Institute/RTL SM SRL
    Chișinău, Moldova, Republic of
    Not yet recruiting
  • NZOZ Bif-Med. s.c.
    Bytom, Poland
    Not yet recruiting
  • Medyczne Centrum Hetmańska
    Poznan, Poland
    Not yet recruiting
  • DC-MED SP z o.o.
    Swidnica, Poland
    Not yet recruiting
  • NZOZ Lecznica MAK-MED s.c.
    Warsaw, Poland
    Not yet recruiting
  • Migre Polskie Centrum Leczenia Migreny
    Wroclaw, Poland
    Not yet recruiting
  • Policlinica CCBR
    Bucarest, Romania
    Not yet recruiting
  • Quantum Medical Bucharest
    Bucharest, Romania
    Not yet recruiting
    • Principal Investigator · Contactjub@nbcd.com · +45 51997709
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Nov 2026, 22 months after the start.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 22 months is above that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2025
First posted
Feb 19, 2025
StartActual
Jan 28, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2026
Last update
Feb 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06833749
Lead sponsor
KeyBioscience AG
Responsible party
Sponsor
First posted
Feb 19, 2025
Start date
Jan 28, 2025
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Feb 19, 2025

Study contacts

KeyBioscience AG Program Director, PhD
Contact
rocco@keybioscience.com
+41 795207086

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion